Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric liver transplant steroid-avoidance study with basiliximab and cyclosporine
2015-003528-29Phase 3
- Sponsor
- Novartis
- Start
- Apr 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of basiliximab, cyclosporine, prednisolone and prednisone in liver transplant (2 arms), sponsored by Novartis. Primary endpoint: Number of participants with at least one biopsy-proven acute rejection episode, graft loss, or death within the first three months post-transplantation.
02
Drugs
basiliximabcyclosporineprednisoloneprednisone
03
Conditions
liver transplant
Beyond the preview
Go deeper on 2015-003528-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003528-29.